Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at ClinicalTrials.gov as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.

Glossary

To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Primary Outcome Measures Adverse Events (Part 1 and Part 2) [Time Frame: Approximately 24 months] Objective response rate (ORR) (Part 2) [Time Frame: Approximately 24 months] Secondary Outcome Measures Maximum observed concentration (Cmax) of rebastinib [ Time Frame: Cycle 1 Day 1, Cycle 2 Day 1 (each cycle is 21 days) ] Measure the Cmax Area ... [More >>]

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Primary Outcome Measures Frequency and severity of adverse events of INBRX-109 [ Time Frame: Up to 2 years ] Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) ... [More >>]

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)

Primary Outcome Measures Overall Survival [ Time Frame: 60 months ] Time to death (from any cause) from randomization Secondary Outcome Measures Survival rate [ Time Frame: 60 months ] Number of deaths (from any ... [More >>]

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

Primary Outcome Measures Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ] The primary outcome will be to prospectively validate a pre-treatment prognostic algorithm to predict survival for MPM patients. Secondary Outcome Measures Evaluation of Molecular Tests Base on RNA Expression [ Time Frame: 4 years ] A secondary outcome will be to evaluate molecular tests that are based ... [More >>]

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Primary Outcome Measures Incidence of adverse events per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 [ Time Frame: Up to 30 days ] The frequency of toxicities will be tabulated by grade across all dose levels and cycles. All subjects who receive any study treatment will be considered ... [More >>]

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Primary Outcome Measures Number of treatment-emergent adverse events [ Time Frame: Up to 12 months ] Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug. Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only) [ Time Frame: Up to approximately 1 month ] PAD ... [More >>]

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Primary Outcome Measures Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0 [ Time Frame: 60 months ] Safety evaluation Secondary Outcome Measures Clinical response [ Time Frame: 60 months ] Clinical response to T-cell infusion, especially change of tumor volume will be evaluated by comparing disease identified by computed tomography, ... [More >>]

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Primary Outcome Measures Incidence and severity of adverse events as assessed by CTCAE v.5.0 [ Time Frame: 6 weeks ] number and severity of adverse events according to NCI CTCAE v.5.0 Secondary Outcome Measures Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 6 weeks ] tumor response scored by RECIST criteria Immune-related Response Evaluation ... [More >>]

DENdritic Cell Immunotherapy for Mesothelioma (DENIM)

Primary Outcome Measures Overall survival rate [ Time Frame: from randomisation to study end (the last visit for the last subject participating in the study and the last data collection point completed) assessed in up to 102 weeks ] The primary outcome measure of this study is to evaluate the overall survival ... [More >>]

Osimertinib In EGFR Mutant Lung Cancer

Primary Outcome Measures Mechanisms of resistance to Osimertinib [ Time Frame: 4 Months ] Evaluated by comparing the genomic changes using targeted next generation sequencing in the post-osimertinib tumor to the pre-treatment tumor specimen. Secondary Outcome Measures Best objective response [ Time Frame: 6 months ] Best objective response will be evaluated via RECIST 1.1 criteria. RECIST1.1 measurements of ... [More >>]

Last update: February 19, 2019. 04:08:16 pm.